ResMed Inc. (NYSE: RMD) Stock Competitors & Peer Comparison
See RMD's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RMD and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMD | $198.99 | -1.86% | 28.9B | 18.47 | $10.77 | +1.21% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.68 | +1.87% | 175.3B | 19.32 | $5.21 | +2.48% |
| ISRG | $345.42 | -11.20% | 142.5B | 41.82 | $9.62 | N/A |
| SYK | $319.87 | -3.42% | 122.6B | 23.89 | $13.39 | +1.09% |
| MDT | $83.20 | -0.43% | 106.5B | 15.04 | $5.53 | +3.43% |
| BSX | $44.03 | -1.32% | 65.4B | 14.20 | $3.10 | N/A |
| EW | $85.73 | -2.40% | 49.4B | 31.75 | $2.70 | N/A |
| DXCM | $76.65 | -1.71% | 29.6B | 32.90 | $2.33 | N/A |
| ZBH | $91.12 | -2.81% | 17.6B | 10.75 | $8.48 | +1.05% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
RMD vs BSX-PA Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RMD's ROE is +0.24%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
RMD vs ABT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ABT trades at $100.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ABT's P/E ratio is 19.32. In terms of profitability, RMD's ROE is +0.24%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ABT's competition here
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RMD vs ISRG Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ISRG trades at $345.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ISRG's P/E ratio is 41.82. In terms of profitability, RMD's ROE is +0.24%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here
Stryker Corporation (NYSE: SYK)
RMD vs SYK Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SYK has a market cap of 122.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SYK trades at $319.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SYK's P/E ratio is 23.89. In terms of profitability, RMD's ROE is +0.24%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SYK's competition here
Medtronic plc (NYSE: MDT)
RMD vs MDT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, MDT has a market cap of 106.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while MDT trades at $83.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas MDT's P/E ratio is 15.04. In terms of profitability, RMD's ROE is +0.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for RMD.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
RMD vs BSX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BSX has a market cap of 65.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BSX trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BSX's P/E ratio is 14.20. In terms of profitability, RMD's ROE is +0.24%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
RMD vs EW Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while EW trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas EW's P/E ratio is 31.75. In terms of profitability, RMD's ROE is +0.24%, compared to EW's ROE of +0.11%. Regarding short-term risk, RMD is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for RMD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
RMD vs DXCM Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while DXCM trades at $76.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas DXCM's P/E ratio is 32.90. In terms of profitability, RMD's ROE is +0.24%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RMD is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for RMD.Check DXCM's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
RMD vs ZBH Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ZBH trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ZBH's P/E ratio is 10.75. In terms of profitability, RMD's ROE is +0.24%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RMD is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
RMD vs ABMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RMD's ROE is +0.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
RMD vs SNN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SNN trades at $30.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SNN's P/E ratio is 16.53. In terms of profitability, RMD's ROE is +0.24%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
RMD vs ALGN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ALGN has a market cap of 12.7B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ALGN trades at $176.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ALGN's P/E ratio is 16.11. In terms of profitability, RMD's ROE is +0.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
RMD vs SWAV Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RMD's ROE is +0.24%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RMD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
RMD vs PEN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PEN trades at $318.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PEN's P/E ratio is 83.11. In terms of profitability, RMD's ROE is +0.24%, compared to PEN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for RMD.Check PEN's competition here
Insulet Corp. (NASDAQ: PODD)
RMD vs PODD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PODD has a market cap of 11.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PODD trades at $164.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PODD's P/E ratio is 30.49. In terms of profitability, RMD's ROE is +0.24%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RMD is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
RMD vs GMED Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, GMED has a market cap of 10.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while GMED trades at $77.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas GMED's P/E ratio is 17.34. In terms of profitability, RMD's ROE is +0.24%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for RMD.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
RMD vs MASI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas MASI's P/E ratio is 44.43. In terms of profitability, RMD's ROE is +0.24%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for RMD.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
RMD vs GKOS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, GKOS has a market cap of 9.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while GKOS trades at $156.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas GKOS's P/E ratio is -182.44. In terms of profitability, RMD's ROE is +0.24%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKR)
RMD vs BRKR Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BRKR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BRKR's P/E ratio is 31.99. In terms of profitability, RMD's ROE is +0.24%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RMD is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BRKR's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
RMD vs BIO-B Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BIO-B has a market cap of 8.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BIO-B trades at $324.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BIO-B's P/E ratio is 96.41. In terms of profitability, RMD's ROE is +0.24%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RMD is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for RMD.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
RMD vs BIO Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BIO trades at $304.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BIO's P/E ratio is 32.81. In terms of profitability, RMD's ROE is +0.24%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BIO's competition here
Inari Medical, Inc. (NASDAQ: NARI)
RMD vs NARI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas NARI's P/E ratio is -59.24. In terms of profitability, RMD's ROE is +0.24%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for RMD.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
RMD vs LIVN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while LIVN trades at $80.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas LIVN's P/E ratio is 20.18. In terms of profitability, RMD's ROE is +0.24%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RMD is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
RMD vs IRTC Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while IRTC trades at $110.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas IRTC's P/E ratio is -205.98. In terms of profitability, RMD's ROE is +0.24%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
RMD vs AXNX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RMD's ROE is +0.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for RMD.Check AXNX's competition here
Integer Holdings Corporation (NYSE: ITGR)
RMD vs ITGR Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ITGR has a market cap of 3.4B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ITGR trades at $95.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ITGR's P/E ratio is 15.81. In terms of profitability, RMD's ROE is +0.24%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RMD is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ITGR's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
RMD vs ESTA Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ESTA trades at $92.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ESTA's P/E ratio is -64.29. In terms of profitability, RMD's ROE is +0.24%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RMD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ESTA's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
RMD vs TMDX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while TMDX trades at $73.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas TMDX's P/E ratio is 30.20. In terms of profitability, RMD's ROE is +0.24%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RMD is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
RMD vs AXGN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AXGN trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AXGN's P/E ratio is 104.87. In terms of profitability, RMD's ROE is +0.24%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
RMD vs NUVA Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RMD's ROE is +0.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NUVA's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
RMD vs UFPT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while UFPT trades at $242.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas UFPT's P/E ratio is 25.21. In terms of profitability, RMD's ROE is +0.24%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check UFPT's competition here
Novocure Ltd (NASDAQ: NVCR)
RMD vs NVCR Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while NVCR trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas NVCR's P/E ratio is -10.41. In terms of profitability, RMD's ROE is +0.24%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
RMD vs BFLY Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BFLY trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BFLY's P/E ratio is -27.54. In terms of profitability, RMD's ROE is +0.24%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
RMD vs ENOV Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ENOV trades at $27.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ENOV's P/E ratio is 8.01. In terms of profitability, RMD's ROE is +0.24%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RMD is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
RMD vs IART Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while IART trades at $19.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas IART's P/E ratio is 8.41. In terms of profitability, RMD's ROE is +0.24%, compared to IART's ROE of -0.48%. Regarding short-term risk, RMD is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for RMD.Check IART's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
RMD vs AHCO Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AHCO trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AHCO's P/E ratio is 24.91. In terms of profitability, RMD's ROE is +0.24%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RMD is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check AHCO's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
RMD vs INSP Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while INSP trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas INSP's P/E ratio is 19.97. In terms of profitability, RMD's ROE is +0.24%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RMD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for RMD.Check INSP's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
RMD vs ATEC Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ATEC trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ATEC's P/E ratio is -77.59. In terms of profitability, RMD's ROE is +0.24%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RMD is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ATEC's competition here
Heska Corporation (NASDAQ: HSKA)
RMD vs HSKA Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RMD's ROE is +0.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for RMD.Check HSKA's competition here
CONMED Corporation (NYSE: CNMD)
RMD vs CNMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CNMD trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CNMD's P/E ratio is 9.51. In terms of profitability, RMD's ROE is +0.24%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CNMD's competition here
IRadimed Corporation (NASDAQ: IRMD)
RMD vs IRMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while IRMD trades at $97.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas IRMD's P/E ratio is 49.13. In terms of profitability, RMD's ROE is +0.24%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RMD is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check IRMD's competition here
Artivion, Inc. (NYSE: AORT)
RMD vs AORT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AORT trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AORT's P/E ratio is 38.51. In terms of profitability, RMD's ROE is +0.24%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check AORT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
RMD vs TNDM Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while TNDM trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas TNDM's P/E ratio is -15.53. In terms of profitability, RMD's ROE is +0.24%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RMD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for RMD.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
RMD vs AVNS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AVNS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AVNS's P/E ratio is 27.76. In terms of profitability, RMD's ROE is +0.24%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RMD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for RMD.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
RMD vs SILK Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SILK's P/E ratio is -18.96. In terms of profitability, RMD's ROE is +0.24%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
RMD vs FNA Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas FNA's P/E ratio is -19.83. In terms of profitability, RMD's ROE is +0.24%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for RMD.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
RMD vs PRCT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PRCT trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PRCT's P/E ratio is -10.56. In terms of profitability, RMD's ROE is +0.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RMD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
RMD vs LMRI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while LMRI trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas LMRI's P/E ratio is -21.67. In terms of profitability, RMD's ROE is +0.24%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, RMD is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check LMRI's competition here
InMode Ltd. (NASDAQ: INMD)
RMD vs INMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, INMD has a market cap of 896.4M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while INMD trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas INMD's P/E ratio is 10.00. In terms of profitability, RMD's ROE is +0.24%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RMD is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
RMD vs CSII Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CSII's P/E ratio is -20.83. In terms of profitability, RMD's ROE is +0.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RMD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for RMD.Check CSII's competition here
Bioventus Inc. (NASDAQ: BVS)
RMD vs BVS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BVS has a market cap of 817M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BVS trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BVS's P/E ratio is 16.08. In terms of profitability, RMD's ROE is +0.24%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
RMD vs SIBN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SIBN has a market cap of 770.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SIBN trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SIBN's P/E ratio is -44.56. In terms of profitability, RMD's ROE is +0.24%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RMD is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SIBN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
RMD vs SSII Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SSII has a market cap of 742.5M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SSII trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SSII's P/E ratio is -72.36. In terms of profitability, RMD's ROE is +0.24%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RMD is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SSII's competition here
CeriBell, Inc. (NASDAQ: CBLL)
RMD vs CBLL Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CBLL has a market cap of 710.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CBLL trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CBLL's P/E ratio is -11.48. In terms of profitability, RMD's ROE is +0.24%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RMD is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
RMD vs TCMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, TCMD has a market cap of 648.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while TCMD trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas TCMD's P/E ratio is 32.66. In terms of profitability, RMD's ROE is +0.24%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
RMD vs CERS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CERS has a market cap of 627.2M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CERS trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CERS's P/E ratio is -62.48. In terms of profitability, RMD's ROE is +0.24%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CERS's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
RMD vs BWAY Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BWAY has a market cap of 617M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BWAY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BWAY's P/E ratio is 39.96. In terms of profitability, RMD's ROE is +0.24%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BWAY's competition here
Surmodics, Inc. (NASDAQ: SRDX)
RMD vs SRDX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RMD's ROE is +0.24%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
RMD vs CTKB Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CTKB has a market cap of 596.6M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CTKB's P/E ratio is -35.54. In terms of profitability, RMD's ROE is +0.24%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
RMD vs APEN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas APEN's P/E ratio is -9.43. In terms of profitability, RMD's ROE is +0.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RMD is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for RMD.Check APEN's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
RMD vs NPCE Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, NPCE has a market cap of 548.2M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while NPCE trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas NPCE's P/E ratio is -27.72. In terms of profitability, RMD's ROE is +0.24%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NPCE's competition here
ZimVie Inc. (NASDAQ: ZIMV)
RMD vs ZIMV Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RMD's ROE is +0.24%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ZIMV's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
RMD vs KIDS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, KIDS has a market cap of 493.5M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while KIDS trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas KIDS's P/E ratio is -18.66. In terms of profitability, RMD's ROE is +0.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RMD is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check KIDS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
RMD vs OFIX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, OFIX has a market cap of 468.1M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while OFIX trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas OFIX's P/E ratio is -47.17. In terms of profitability, RMD's ROE is +0.24%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
RMD vs CLPT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CLPT has a market cap of 454.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CLPT trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CLPT's P/E ratio is -15.00. In terms of profitability, RMD's ROE is +0.24%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RMD is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
RMD vs PACB Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PACB has a market cap of 447.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PACB trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PACB's P/E ratio is -2.94. In terms of profitability, RMD's ROE is +0.24%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RMD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PACB's competition here
Varex Imaging Corporation (NASDAQ: VREX)
RMD vs VREX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, VREX has a market cap of 444.2M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while VREX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas VREX's P/E ratio is 11.11. In terms of profitability, RMD's ROE is +0.24%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RMD is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
RMD vs DCTH Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, DCTH has a market cap of 442.2M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while DCTH trades at $12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas DCTH's P/E ratio is 1281.00. In terms of profitability, RMD's ROE is +0.24%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RMD is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for RMD.Check DCTH's competition here
Electromed, Inc. (AMEX: ELMD)
RMD vs ELMD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ELMD has a market cap of 348.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ELMD trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ELMD's P/E ratio is 36.00. In terms of profitability, RMD's ROE is +0.24%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RMD is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ELMD's competition here
Carlsmed, Inc. (NASDAQ: CARL)
RMD vs CARL Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CARL has a market cap of 317M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CARL trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CARL's P/E ratio is -4.65. In terms of profitability, RMD's ROE is +0.24%, compared to CARL's ROE of -0.62%. Regarding short-term risk, RMD is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CARL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
RMD vs AVR Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, AVR has a market cap of 310.9M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while AVR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas AVR's P/E ratio is -3.79. In terms of profitability, RMD's ROE is +0.24%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RMD is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check AVR's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
RMD vs SMLR Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RMD's ROE is +0.24%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, RMD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
RMD vs TMCI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, TMCI has a market cap of 279M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while TMCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas TMCI's P/E ratio is -4.57. In terms of profitability, RMD's ROE is +0.24%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RMD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check TMCI's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
RMD vs SGHT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SGHT trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SGHT's P/E ratio is -7.08. In terms of profitability, RMD's ROE is +0.24%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RMD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SGHT's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
RMD vs MGRM Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas MGRM's P/E ratio is -12.00. In terms of profitability, RMD's ROE is +0.24%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, RMD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for RMD.Check MGRM's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
RMD vs CATX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CATX has a market cap of 230.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CATX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CATX's P/E ratio is -2.12. In terms of profitability, RMD's ROE is +0.24%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RMD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CATX's competition here
RxSight, Inc. (NASDAQ: RXST)
RMD vs RXST Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, RXST has a market cap of 229.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while RXST trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas RXST's P/E ratio is -7.71. In terms of profitability, RMD's ROE is +0.24%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RMD is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RXST's competition here
Nevro Corp. (NYSE: NVRO)
RMD vs NVRO Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RMD's ROE is +0.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check NVRO's competition here
Picard Medical, Inc. (AMEX: PMI)
RMD vs PMI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PMI has a market cap of 220.4M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PMI's P/E ratio is -0.12. In terms of profitability, RMD's ROE is +0.24%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RMD is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PMI's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
RMD vs SENS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, SENS has a market cap of 213.6M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while SENS trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas SENS's P/E ratio is -2.56. In terms of profitability, RMD's ROE is +0.24%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RMD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SENS's competition here
Profound Medical Corp. (NASDAQ: PROF)
RMD vs PROF Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, PROF has a market cap of 207.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas PROF's P/E ratio is -5.52. In terms of profitability, RMD's ROE is +0.24%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RMD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PROF's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
RMD vs FOCL Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, FOCL has a market cap of 203.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while FOCL trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas FOCL's P/E ratio is -6.99. In terms of profitability, RMD's ROE is +0.24%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, RMD is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check FOCL's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
RMD vs ANIK Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ANIK has a market cap of 202.9M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ANIK trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ANIK's P/E ratio is 31.12. In terms of profitability, RMD's ROE is +0.24%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ANIK's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
RMD vs BSGM Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RMD's ROE is +0.24%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, RMD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BSGM's competition here
Quanterix Corporation (NASDAQ: QTRX)
RMD vs QTRX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, QTRX has a market cap of 182.1M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while QTRX trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas QTRX's P/E ratio is -2.42. In terms of profitability, RMD's ROE is +0.24%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RMD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
RMD vs INGN Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, INGN has a market cap of 180.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while INGN trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas INGN's P/E ratio is -7.32. In terms of profitability, RMD's ROE is +0.24%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RMD is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for RMD.Check INGN's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
RMD vs MDGS Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RMD's ROE is +0.24%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check MDGS's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
RMD vs TLSI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, TLSI has a market cap of 162.6M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while TLSI trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas TLSI's P/E ratio is -2.55. In terms of profitability, RMD's ROE is +0.24%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, RMD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check TLSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
RMD vs QIPT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RMD's ROE is +0.24%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for RMD.Check QIPT's competition here
CVRx, Inc. (NASDAQ: CVRX)
RMD vs CVRX Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, CVRX has a market cap of 130.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while CVRX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas CVRX's P/E ratio is -2.43. In terms of profitability, RMD's ROE is +0.24%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to CVRX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CVRX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
RMD vs RCEL Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, RCEL has a market cap of 126.7M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while RCEL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas RCEL's P/E ratio is -3.25. In terms of profitability, RMD's ROE is +0.24%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, RMD is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RCEL's competition here
iCAD, Inc. (NASDAQ: ICAD)
RMD vs ICAD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RMD's ROE is +0.24%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, RMD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
RMD vs OWLT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, OWLT has a market cap of 101.1M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while OWLT trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas OWLT's P/E ratio is -39.93. In terms of profitability, RMD's ROE is +0.24%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, RMD is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check OWLT's competition here
Solana Company (NASDAQ: HSDT)
RMD vs HSDT Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, HSDT has a market cap of 99.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas HSDT's P/E ratio is -0.02. In terms of profitability, RMD's ROE is +0.24%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, RMD is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
RMD vs HJLI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas HJLI's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, RMD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check HJLI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
RMD vs LUCD Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, LUCD has a market cap of 97.2M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while LUCD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas LUCD's P/E ratio is -2.57. In terms of profitability, RMD's ROE is +0.24%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, RMD is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check LUCD's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
RMD vs ASXC Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas ASXC's P/E ratio is -1.12. In terms of profitability, RMD's ROE is +0.24%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, RMD is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ASXC's competition here
Rapid Micro Biosystems, Inc. (NASDAQ: RPID)
RMD vs RPID Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, RPID has a market cap of 93.8M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while RPID trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas RPID's P/E ratio is -1.85. In terms of profitability, RMD's ROE is +0.24%, compared to RPID's ROE of -1.32%. Regarding short-term risk, RMD is less volatile compared to RPID. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RPID's competition here
QT Imaging Holdings, Inc. (NASDAQ: QTI)
RMD vs QTI Comparison July 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28.9B. In comparison, QTI has a market cap of 89M. Regarding current trading prices, RMD is priced at $198.99 on the NYSE, while QTI trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.47, whereas QTI's P/E ratio is -4.82. In terms of profitability, RMD's ROE is +0.24%, compared to QTI's ROE of -63.31%. Regarding short-term risk, RMD is less volatile compared to QTI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check QTI's competition here